Member Info for Soupdragon78

Older / FX, he's still on at Promentra. As you say older its his consulting business, but if his personal reasons were serious then that would see him step down across all aspects.
As non-exec chairman he would hardly be involved regularly or even on a weekly basis. I just don't see why it couldn't wait to be released with positive news if that was only a few weeks away.

I see Blackwell is still staying on as Director of his other ventures, just not NFX.

As well as time and knowledge.

FX, they've changed legals again, now not Cooleys.

" I look forward to being able to communicate in more detail ..."

Being able to.....

Whats holding her back?

Nope

Chasing the spikes there yuyu's? Be careful now.

Maybe Anne suggested releasing something positive and that made him ill?

The rotating door strikes again.

FX it was just the uncrossing trade after the 9am auction. Not a person as such. Hence the trades are now back to normal.

Annoyingly they are still walking down the ask.

Older, its likely a sell order as they are walking down the ask with each buy. The day started with 2.54 to buy, now 2.53.

Only 15% working? Sounds quite disappointing for both parties involved.

Not seeing anything here, only a bit and a sell

I'm curious as to what Senari are up to. Brindley is part of the management team over there and they seem to be expecting results Q1 2021. It appears to be COPD oriented, but I'm curious to find out what their 'novel ' approach is.

"Senari Pharma is a seed-stage pharma company targeting a $2bn market through the development of an inhaled therapeutic for obstructive lung disease using known molecules in a novel way....

The company is reducing the risk of formulation development and time to market through leveraging well-established inactive ingredients and device components...

The management team is completed by two senior pharmaceutical executives: Dr Anne Brindley, a recognised industry expert in inhaled product development with a central role in the approval of two major inhaled product brands; ...

The company is now seeking additional investment to coincide with the attainment of two key milestones in Q1 2021, in order to fund continued formulation development and progression into initial clinical trials..."

Filter, the company continually worked on NXP002 through the past year, including developing the formulation and initiating pre-clinical trials.

Filter, in fairness to the company, they were silent on Ebers in the interims because nothing had happened on that within the period, nothing to report.

NFX only do work as and when requested by Ebers. For a while now Ebers have been focussed on aligning their funding and preparing what they have to move forward, as opposed to funding new patents.
I believe once they complete their RTO and fund raise we will start to hear more.

Just as a quick summary of near term news flow. Lots to be going on.

NXP001 - Oxilio - Option for global licensing in oncology - Expires end Q1
NXP002 - Pre-clinical study results for benefits of using alone or in combination with current standard of care - Due Q1
NXP002 - Innovate UK grant - Due Q1
NXP004 - Pre-clinical results anti-fibrotic and anti-inflammatory against standard of care - Due Q1
NXP004 - Evaluation of new IP for development of multi-billion dollar drug indications.
Ebers - RTO update and prospectus - Due Q1

Should have added, I was slightly dismayed that Blackwell decided not to RNS that they has submitted new patents for NXP004 until he mentioned it in the interims. Previously the company would announce these individually, helping sentiment.

Filter, Ebers work will come as and when Ebers dictate, it is mostly due to their funding which will be in a good place after their listing on TSX and fund raise.
Vistagen we have to write off, its a shame but thats the way things go sometimes, you can't be successful in everything. That said I would be pleasantly surprised to be wrong.

The key items for me are those that are actively being undertaken, NXP002 and NXP004 study results. Both of these were initiated before xmas (exactly when we don't know) but should return results very soon.

I just hope the company don't sit on any positives and try to release everything as a single update later on.

Well I'm hoping they have the sense to release news about NXP004 in the very (very) near term and not hang onto it until a wider update.

The full data was due back before xmas, so they should have had a decent amount of time to study it (assuming it came back as predicted).
Whilst it will only be news on what they planned to do, I would like to think it would help give confidence.